Item 2.01 Completion of Acquisition or Disposition of Assets.

On March 31, 2020, General Electric Company (the "Company" or "GE") completed the sale of its BioPharma business in its Healthcare segment to Danaher Corporation ("Danaher") for $21.4 billion ($21.1 billion of total consideration, reflecting $0.3 billion of working capital adjustments to the contractual price). The consideration consisted of $20.7 billion in cash and $0.4 billion of pension liabilities that were assumed by Danaher. The Company received cash of $20.3 billion on March 31st and an additional $0.4 billion on April 1st.

The unaudited pro forma financial information giving effect to the BioPharma sale transaction is filed herewith as Exhibit 99.

Item 9.01 Financial Statements and Exhibits.

(b) Pro Forma Financial Information.

The following unaudited pro forma financial information of the Company is filed as Exhibit 99 to this Report on Form 8-K and is incorporated herein by reference:



•         Unaudited Pro Forma Condensed Consolidated Statement of Financial
          Position as of December 31, 2019.


•         Unaudited Pro Forma Condensed Consolidated Statement of Earnings (Loss)
          for the year ended December 31, 2019.

• Notes to the Unaudited Pro Forma Condensed Consolidated Financial Statements.






(d) Exhibits.

99 . General Electric Company Unaudited Pro Forma Condensed Consolidated Financial Statements.

104. The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.




                                      (2)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses